Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446405 · ClinicalTrials.gov registry record · Phase 3
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
A Phase 3 study of Prostatic Neoplasms, sponsored by University of Sydney.
- Active
- Registry status
- Phase 3
- Development phase
- 1,125
- Enrollment target
- 20
- Study locations
NCT02446405 is a Phase 3 study of Prostatic Neoplasms that is active but no longer recruiting, run by University of Sydney. The registered enrollment target is 1,125 participants, above the 497-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT02446405, a Phase 3 study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by University of Sydney.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,125 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG NSAA
- DRUG LHRHA or Surgical Castration
Study Locations (20)
New South Wales
- Chris O'Brien Lifehouse - Camperdown
- Coffs Harbour Health Campus - Coffs Harbour
- Concord Cancer Centre - Concord Repatriation General Hospital - Concord
- St Vincent's Hospital Sydney - Darlinghurst
- Nepean Cancer Care Centre - Kingswood
- St. George Hospital - Kogarah
- Central West Cancer Services - Orange
- Port Macquarie Base Hospital - Port Macquarie
- Prince of Wales Hospital - Randwick
- Genesis Care North Shore - St Leonards
- Tamworth Rural Referral Hospital - Tamworth
- The Tweed Hospital - Tweed Heads
- Riverina Cancer Care Centre - Wagga Wagga
- Sydney Adventist Hospital - Wahroonga
- Wollongong Hospital - Wollongong
Queensland
- Sunshine Coast University Hospital - Birtinya
- Townsville Hospital - Douglas
- Royal Brisbane and Women's Hospital - Herston
Massachusetts
- Dana Farber Cancer Institute - Boston
Northern Territory
- Royal Darwin Hospital - Tiwi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,125 participants |
| Start Date | 2014-03 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446405
The ClinicalTrials.gov registry entry for NCT02446405 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,125 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 497-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (126% higher). The listed sponsor is University of Sydney, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Enzalutamide is the first listed.
NCT02446405 reports 20 study locations spanning 4 distinct geographic areas - top geographies include New South Wales, Queensland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02446405 about?
NCT02446405 is a clinical study titled "Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer". The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnose...
What is the current status of trial NCT02446405?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,125 participants. The study started on 2014-03. Estimated completion is 2027-06-30.
What conditions does trial NCT02446405 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02446405?
The interventions under investigation include: Enzalutamide (DRUG), NSAA (DRUG), LHRHA or Surgical Castration (DRUG).
Who is sponsoring clinical trial NCT02446405?
This trial is sponsored by University of Sydney, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02446405 being conducted?
This trial has 20 study locations across Massachusetts, New South Wales, Northern Territory, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RECRUITING · Phase 3
-
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 3
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
ACTIVE NOT RECRUITING · Phase 3
-
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.